Thrombophilia Market Report 2025

The thrombophilia market size has grown strongly in recent years. It will grow from $17.03 billion in 2024 to $18.35 billion in 2025 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to increasing awareness, research and development in anticoagulant therapies, aging population, genetic research, increased incidence of thrombotic disorders.

The thrombophilia market size is expected to see strong growth in the next few years. It will grow to $25.12 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to personalized medicine, emergence of novel therapies, integration of artificial intelligence, healthcare policy and regulation, increased patient education and empowerment. Major trends in the forecast period include technological advancements, expanded role of telemedicine, rising incidence rates, biopharmaceutical developments, collaborative research initiatives.

The growing elderly population is expected to drive the expansion of the thrombophilia market in the future. The elderly population consists of individuals aged 65 and older, with the proportion of the dependent population calculated as the total elderly and youth population in relation to the overall population. Thrombophilic risk factors are prevalent among older adults, enabling the identification of a population at risk for poor clinical outcomes. As a result, the increasing elderly population will boost demand for thrombophilia drugs. For example, according to data from America’s Health Rankings, a U.S.-based organization that evaluates health outcomes, in 2022, over 56 million adults aged 65 and older made up approximately 16.9% of the total U.S. population. This number is projected to rise to more than 73.1 million by 2030. Therefore, the increase in the elderly population is fueling the growth of the thrombophilia market.

The increasing prevalence of thrombophilic conditions is anticipated to contribute significantly to the growth of the thrombophilia market in the years ahead. Thrombophilic diseases, characterized by an elevated predisposition to blood clot formation (thrombosis), play a crucial role in shaping the thrombophilia market landscape, influencing diagnosis, treatment approaches, and ongoing research. For example, in August 2023, data from the Nuffield Trust revealed that the UK had the highest number of cases of Deep Vein Thrombosis (DVT) among eight nations providing data. In 2021, there were 352 cases, increasing to 377 for every 100,000 hospital discharges in 2022. This surge in the prevalence of thrombophilic conditions serves as a key factor driving the thrombophilia market.

Technological advancements are emerging as a key trend gaining traction in the thrombophilia market. Leading companies in the market are focusing on developing innovative technologies to maintain their competitive edge. For example, in May 2023, researchers at the University of California, San Diego, developed a revolutionary technology called Eloctate, which has the potential to transform hemophilia treatment. This cutting-edge approach uses a novel fusion protein that significantly improves the stability and half-life of coagulation factors in the bloodstream. By integrating this technology with existing therapies, the researchers aim to create long-acting drugs that require less frequent dosing, enhancing patient compliance and overall quality of life.

Major companies in the thrombophilia market are strategically pursuing partnerships to advance the development of biosynthetic heparin. Strategic partnerships involve leveraging each other's strengths and resources for mutual benefits and success. For example, in January 2022, Optimvia, LLC, a US-based biotechnology company, announced a partnership with Ginkgo Bioworks with the aim of enhancing the efficiency of biosynthetic heparin synthesis. Optimvia plans to utilize Ginkgo's cell and enzyme engineering systems, along with its fermentation manufacturing capabilities, to expedite the improvement of its biosynthetic heparin production method. The collaboration aims to create commercially viable, cost-effective, and safe biosynthetic heparin, potentially reducing the global dependence on heparin sourced from livestock. Ginkgo Bioworks, a US-based company specializing in cell programming, provides a platform to support this innovative partnership in the thrombophilia market.

In March 2022, Pfizer Inc., a prominent US-based pharmaceutical company, successfully completed the acquisition of Arena Pharmaceuticals for a substantial sum of $6.7 billion. As a result of this acquisition, Arena Pharmaceuticals has now become a subsidiary of Pfizer. This strategic move is anticipated to foster innovations aimed at enhancing the lives of individuals grappling with immuno-inflammatory disorders. Arena Pharmaceuticals, Inc., the acquired entity, is based in the United States and is dedicated to developing treatments for thromboembolic disorders affecting the arterial blood vessels. The acquisition reflects Pfizer's commitment to expanding its portfolio and capabilities in the field of pharmaceuticals, particularly in addressing disorders related to the immune and inflammatory systems.

Major companies operating in the thrombophilia market include Pfizer Inc., F. Hoffmann-La Roche Limited, Changzhaou Qianhong Bio-pharma Co. Limited, Fresenius Kabi AG, Hebei Changshan Biochemical Pharmaceutical Co. Limited, Hikma Pharmaceuticals PLC., Novartis AG, Shanghai Fosun Pharmaceutical (Group) Co. Ltd., Shenzhen Hepalink Pharmaceutical Group Co. Limited, Teva Pharmaceutical Industries Limited, Yino Pharma Limited, Sanofi SA, Eisai Co. Limited, Boehringer Ingelheim GmbH, Instrumentation Laboratory SpA, Johnson & Johnson, Laurus Lab, Bristol-Myers Squibb, Roche, Abbott, C. H. Boehringer Sohn, Portola Pharmaceuticals, Daiichi Sankyo, Bayer Group, GlaxoSmithKline plc, CSL Behring.

North America was the largest region in the thrombophilia market in 2024. The regions covered in the thrombophilia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the thrombophilia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Thrombophilia denotes a blood condition heightening the likelihood of clot formation within veins and arteries, potentially stemming from arterial or venous clotting or a hereditary (genetic) or acquired predisposition. This condition bears the potential to trigger severe health complications such as heart attacks, strokes, kidney failure, and pulmonary embolisms.

The primary thrombophilia types encompass factor V Leiden, prothrombin 20210, antiphospholipid syndrome, among others. Factor V Leiden involves a mutation in one of the blood-clotting factors. Treatment options include medications such as Heparin, Warfarin, and others, administered through various routes including oral and parenteral. End-users of these treatments span across hospitals, home health agencies, specialty centers, and similar entities.

The thrombophilia market research report is one of a series of new reports from. The Business Research Company that provides thrombophilia market statistics, including thrombophilia industry global market size, regional shares, competitors with a thrombophilia market share, detailed thrombophilia market segments, market trends and opportunities, and any further data you may need to thrive in the thrombophilia industry. This thrombophilia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The thrombophilia market consists of sales of rivaroxaban, apixaban, and thrombolytics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.